Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
Source: View publication →
In patients with advanced or recurrent endometrial cancer progressing after prior platinum-based chemotherapy and immunotherapy, the antibody-drug conjugate sacituzumab tirumotecan significantly improved both progression-free and overall survival compared with standard physician's choice chemotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
For patients with advanced endometrial cancer whose disease has progressed following standard-of-care platinum-based chemotherapy and immunotherapy, therapeutic options have historically been scarce and poorly efficacious. The robust 32% reduction in the risk of death and a nearly 7-month absolute improvement in median overall survival establish sacituzumab tirumotecan (a TROP2-directed antibody-drug conjugate) as a highly effective new standard of care in this difficult-to-treat setting.
Historical Context
The therapeutic paradigm for advanced endometrial cancer evolved rapidly in recent years with the integration of anti-PD-1/PD-L1 checkpoint inhibitors alongside frontline platinum-based chemotherapy (following landmark trials such as RUBY and NRG-GY018). However, for patients who inevitably progress on these regimens, there has been no established consensus on second-line therapy. Conventional single-agent chemotherapy (like doxorubicin or paclitaxel) traditionally yielded poor response rates and limited survival. Sacituzumab tirumotecan represents the first targeted TROP2-directed antibody-drug conjugate to demonstrate a dual survival benefit over chemotherapy in this newly defined, post-immunotherapy patient population.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of sacituzumab tirumotecan, and why is TROP2 an appealing target in advanced epithelial tumors like endometrial cancer?
Key Response
Sacituzumab tirumotecan is an antibody-drug conjugate (ADC). It targets TROP2 (trophoblast cell-surface antigen 2), a transmembrane glycoprotein that is frequently overexpressed in many epithelial cancers and is associated with tumor proliferation and invasion. The monoclonal antibody is linked to a highly potent topoisomerase I inhibitor payload. When the antibody binds to TROP2 on the cancer cell surface, the ADC is internalized, and the payload is released intracellularly, causing DNA double-strand breaks and subsequent apoptosis. This mechanism allows for targeted delivery of chemotherapy directly to tumor cells, minimizing systemic toxicity while bypassing traditional resistance mechanisms.
Based on the typical toxicity profile of TROP2-directed ADCs with topoisomerase I inhibitor payloads, what specific adverse events should a resident proactively monitor and manage in a patient receiving sacituzumab tirumotecan for recurrent endometrial cancer?
Key Response
Residents must proactively monitor for the class-effect toxicities associated with TROP2/Topo-I ADCs, which primarily include severe neutropenia and gastrointestinal toxicity (especially diarrhea). Management often requires regular complete blood counts, prophylactic or reactive use of G-CSF for neutropenia, and aggressive administration of anti-diarrheals like loperamide (similar to irinotecan protocols). Furthermore, vigilant monitoring for drug-induced interstitial lung disease (ILD) or pneumonitis is critical, as this is a known, potentially fatal risk with several topoisomerase I-based ADCs.
Given the recent integration of immunotherapy and platinum-based chemotherapy in the first-line setting for advanced endometrial cancer, how does the mismatch repair (MMR) status of the tumor influence the clinical interpretation of sacituzumab tirumotecan's efficacy in this post-immunotherapy trial?
Key Response
Mismatch repair deficient (dMMR) tumors are highly responsive to upfront immunotherapy, often with durable responses, whereas MMR proficient (pMMR) tumors have more modest benefits and faster rates of progression. A fellow must evaluate the trial's subgroup analyses to determine if sacituzumab tirumotecan's benefit is consistent across both MMR subgroups. Because pMMR patients have fewer effective subsequent options and typically progress faster on initial chemo-immunotherapy, demonstrating a robust survival benefit in the pMMR subgroup fills a massive unmet clinical need in gynecologic oncology.
With the demonstration of both PFS and OS benefits with sacituzumab tirumotecan in the post-immunotherapy setting, how does this trial alter the systemic therapy sequencing paradigm for recurrent endometrial cancer, particularly regarding the use of lenvatinib plus pembrolizumab?
Key Response
Historically, lenvatinib plus pembrolizumab was the standard second-line therapy for pMMR endometrial cancer. However, with pembrolizumab and dostarlimab moving to the first-line setting alongside chemotherapy, the utility of rechallenging with lenvatinib/pembrolizumab in the second line is highly questionable and often yields poor outcomes. The TroFuse-005 trial establishes sacituzumab tirumotecan as a potent, immediate post-platinum/post-IO option, effectively replacing older single-agent cytotoxic chemotherapies and necessitating a major practice-changing shift in how we sequence therapies for these patients.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In an open-label Phase 3 trial like TroFuse-005 evaluating an ADC against treatment of physician's choice, how might informative censoring impact the assessment of Progression-Free Survival (PFS), and what statistical methodologies should be applied to ensure the robustness of the PFS findings?
Key Response
In open-label trials, patients randomized to standard chemotherapy (control) may withdraw consent early due to disappointment with the assignment or toxicity, leading to asymmetric dropout and informative censoring. This can artificially inflate the control arm's median PFS if those dropping out were destined to progress quickly. A PhD researcher would look for the use of Blinded Independent Central Review (BICR) to prevent investigator bias in radiographic assessment, and the application of sensitivity analyses such as inverse probability of censoring weighting (IPCW) or tipping point analyses to confirm that the PFS benefit remains statistically significant regardless of the dropout pattern.
As a peer reviewer evaluating the TroFuse-005 manuscript, how would you scrutinize the 'Treatment of Physician's Choice' (TPC) control arm to determine if the Overall Survival benefit represents a true superiority of sacituzumab tirumotecan versus merely an underperforming or outdated control arm?
Key Response
A rigorous reviewer must evaluate the exact composition of the TPC arm (e.g., paclitaxel, doxorubicin, pegylated liposomal doxorubicin) and the proportion of patients receiving each. If the TPC therapies were dosed suboptimally, or if control arm patients lacked access to adequate standard-of-care post-progression therapies (poor subsequent crossover options), the OS benefit of the experimental drug might be exaggerated. The reviewer would demand historical benchmarking of the control arm's performance to ensure it accurately reflects contemporary, real-world survival outcomes for this specific post-IO/post-platinum population.
How should guideline committees like NCCN and ESMO integrate the findings of TroFuse-005 into the treatment algorithms for recurrent endometrial cancer, specifically regarding the Level of Evidence for sacituzumab tirumotecan compared to existing single-agent cytotoxic options?
Key Response
Current NCCN guidelines for recurrent endometrial cancer progressed on platinum and immunotherapy list non-targeted single agents like paclitaxel, doxorubicin, or liposomal doxorubicin, which generally yield low response rates and poor survival. The demonstration of dual PFS and OS benefits in a randomized Phase 3 trial constitutes Category 1 evidence. Guideline committees should strongly consider updating algorithms to elevate sacituzumab tirumotecan to the preferred Category 1 recommendation for second-line or subsequent therapy in this specific patient population, superseding older chemotherapies.
Clinical Landscape
Noteworthy Related Trials
GARNET Trial
Tested
Dostarlimab
Population
Patients with mismatch repair-deficient advanced or recurrent endometrial cancer
Comparator
None (single-arm)
Endpoint
Objective response rate
KEYNOTE-775 Trial
Tested
Lenvatinib plus Pembrolizumab
Population
Advanced endometrial cancer previously treated with platinum-based chemotherapy
Comparator
Treatment of physician's choice chemotherapy
Endpoint
Progression-free survival and overall survival
DESTINY-PanTumor02 Trial
Tested
Trastuzumab deruxtecan (T-DXd)
Population
Patients with HER2-expressing previously treated advanced solid tumors including endometrial cancer
Comparator
None (single-arm)
Endpoint
Objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis